Maprotylina en es it fr

Maprotylina Brand names, Maprotylina Analogs

Maprotylina Brand Names Mixture

  • No information avaliable

Maprotylina Chemical_Formula


Maprotylina RX_link

No information avaliable

Maprotylina fda sheet

Maprotylina msds (material safety sheet)

Maprotylina MSDS

Maprotylina Synthesis Reference

M. Wilhelm, et al. Helv. Chim. Acta. 52, 1385 (1969)

Maprotylina Molecular Weight

277.403 g/mol

Maprotylina Melting Point

93 oC

Maprotylina H2O Solubility

Slightly soluble

Maprotylina State


Maprotylina LogP


Maprotylina Dosage Forms

Tablet (10, 25, 50, and 75mg film coated)

Maprotylina Indication

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Maprotylina Pharmacology

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline re-uptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Maprotylina Absorption

Completely absorbed following oral administration

Maprotylina side effects and Toxicity

LD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

Maprotylina Patient Information

No information avaliable

Maprotylina Organisms Affected

Humans and other mammals